Moreover, these results showed that the PD1/PDL1 and CTLA-4 pathways have a distinct role in modulating immune activity [54], and also confirmed that CTLA-4 blockade is effective in HCC, as in previous clinical trials [41,55]. The gene discussed is CD274; the disease is hepatocellular carcinoma.